Apogee Therapeutics Advances zumilokibart Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy APGE?
"In the last 12 months we made meaningful progress across our pipeline, including advancing zumilokibart with positive APEX Phase 2 Part A results, as well as proof-of-concept data from our Phase 1b trial in asthma," said Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics. "We are now focused on proving out the potential of zumilokibart in AD with the APEX Phase 2 Part A 52-week maintenance readout expected in March, followed by the APEX Phase 2 Part B dose optimization readout expected in the second quarter and Phase 3 initiation targeted by year end. Later this year, we plan to provide additional details on development for expansion indications including asthma and EoE, further advancing our vision for zumilokibart as a pipeline-in-a-product. In the second half of 2026, our expected head-to-head readout of APG279 compared to DUPIXENT has potential to be the first proof-of-concept for Apogee's combination programs in AD. With cash runway into the second half of 2028, we believe we are well positioned to work toward launching a transformative therapy this decade as we build a leading I&I biotech."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 75.370
Low
83.00
Averages
105.67
High
137.00
Current: 75.370
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apogee Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Widening Financial Loss: Apogee Therapeutics reported a net loss of $255.8 million for 2025, up from $182.1 million in 2024, indicating ongoing pressure from R&D investments that may affect future financing capabilities.
- Pipeline Strategy Focus: The company employs a 'pipeline-in-a-product' strategy centered on Zumilokibart, with multiple pivotal data readouts expected in 2026, which will significantly impact its market positioning and investor confidence.
- Clinical Trial Progress: The APEX Phase 2 trial for Zumilokibart is set to release 52-week Part A data this month, while 16-week Part B data is anticipated in Q2 2026, with successful results paving the way for Phase 3 initiation.
- Strong Cash Position: Apogee ended 2025 with a robust cash reserve of $902.9 million, providing a runway into the second half of 2028, thereby supporting the advancement toward the launch of Zumilokibart in 2029.
See More
Apogee Therapeutics Reports FY Net Loss of $255.8M
- Financial Performance: Apogee Therapeutics reported a net loss of $255.8 million for FY 2023, indicating high expenditures in R&D and marketing that could negatively impact future financing capabilities and shareholder confidence.
- Clinical Progress: The company has made advancements in the interim Phase Ib results of Zumilokibart for mild-to-moderate asthma, although specific data was not disclosed; this progress may lay the groundwork for future product launches and enhance market competitiveness.
- Strategic Outlook: Apogee Therapeutics is viewed as reaching a critical inflection point in immunology by 2026, and successful new therapy launches could improve financial health and attract more investor interest.
- Industry Engagement: The company presented at the 2025 Citi Annual Global Healthcare Conference, and while detailed outcomes were not provided, such events help raise brand awareness and may facilitate future collaboration opportunities.
See More
Great Point Partners Increases Stake in Apogee Therapeutics
- Share Acquisition: On February 17, 2026, Great Point Partners purchased 70,000 shares of Apogee Therapeutics (APGE) for an estimated $4.41 million, indicating strong confidence in the company's future prospects.
- Asset Value Increase: This transaction boosted the fund's quarter-end position value by $16.15 million, reflecting the dual impact of new share acquisitions and stock price appreciation, demonstrating the effectiveness of its biotechnology investment strategy.
- Increased Ownership Stake: Apogee Therapeutics now represents 9.15% of the fund's reportable assets, making it the largest holding, which underscores the fund's trust in its biologic platform, particularly in the concentrated investment in immunology.
- Strong Financial Position: As of February 17, 2026, APGE shares were priced at $69.64, up 100% over the past year, showcasing robust market performance and potential growth opportunities, which are likely to continue attracting investor interest.
See More
Great Point Partners Increases Apogee Holdings by 70,000 Shares
- Share Increase: Great Point Partners increased its position in Apogee Therapeutics by 70,000 shares in Q4 2026, with an estimated transaction value of $4.41 million, reflecting confidence in the company's future prospects.
- Market Value Growth: The fund's quarter-end position value rose by $16.15 million, demonstrating the dual impact of new share acquisitions and stock price appreciation, further solidifying its investment stance in the biotech sector.
- Investment Concentration: Apogee has become the fund's largest holding, now accounting for approximately 9.15% of reportable assets, indicating its significance in the portfolio and a strong focus on the biopharmaceutical field.
- Strong Financial Position: With $913 million in cash, Apogee's financial health appears robust, providing a runway into the second half of 2028, which mitigates financial risk and supports future R&D and market expansion.
See More
Apogee Therapeutics Announces Upcoming Conference Participation
- Management Conference Schedule: Apogee Therapeutics will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, showcasing its latest advancements in biotechnology, which is expected to attract investor interest.
- Multiple Conference Participation: The management team will also attend the UBS Biotech Summit on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026, further enhancing the company's visibility and investor relations in the biotech sector.
- Product Development Outlook: Apogee is advancing its antibody programs, particularly Zumilokibart (APG777) for Atopic Dermatitis (AD) and asthma, aiming to fill gaps in existing therapies and meet market demand.
- Market Positioning and Goals: The company is committed to achieving best-in-class efficacy through monotherapies and combinations targeting four validated indications, striving to lead in the immunology and inflammation market and enhance patient treatment experiences.
See More
Perceptive Advisors Increases Stake in Apogee Therapeutics
- Share Increase: On February 17, 2026, Perceptive Advisors disclosed a purchase of 978,662 shares of Apogee Therapeutics, with an estimated transaction value of $61.64 million, indicating strong confidence in the company.
- Stake Proportion Rise: Following this acquisition, Perceptive Advisors' total holdings in Apogee reached 2,330,651 shares, representing 3.14% of its 13F AUM, reflecting ongoing interest in the biotech sector.
- Outstanding Stock Performance: As of February 17, 2026, Apogee's shares were priced at $69.64, up 99.4% over the past year, significantly outperforming the S&P 500 by 78.67 percentage points, showcasing market optimism for its future growth.
- Positive Financial Outlook: Apogee anticipates fiscal 2026 sales of approximately $1.39 billion, with adjusted EPS between $3.40 and $3.50, indicating potential in clinical development and commercialization, attracting long-term investor interest.
See More
Apogee Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Widening Financial Loss: Apogee Therapeutics reported a net loss of $255.8 million for 2025, up from $182.1 million in 2024, indicating ongoing pressure from R&D investments that may affect future financing capabilities.
- Pipeline Strategy Focus: The company employs a 'pipeline-in-a-product' strategy centered on Zumilokibart, with multiple pivotal data readouts expected in 2026, which will significantly impact its market positioning and investor confidence.
- Clinical Trial Progress: The APEX Phase 2 trial for Zumilokibart is set to release 52-week Part A data this month, while 16-week Part B data is anticipated in Q2 2026, with successful results paving the way for Phase 3 initiation.
- Strong Cash Position: Apogee ended 2025 with a robust cash reserve of $902.9 million, providing a runway into the second half of 2028, thereby supporting the advancement toward the launch of Zumilokibart in 2029.
See More
Apogee Therapeutics Reports FY Net Loss of $255.8M
- Financial Performance: Apogee Therapeutics reported a net loss of $255.8 million for FY 2023, indicating high expenditures in R&D and marketing that could negatively impact future financing capabilities and shareholder confidence.
- Clinical Progress: The company has made advancements in the interim Phase Ib results of Zumilokibart for mild-to-moderate asthma, although specific data was not disclosed; this progress may lay the groundwork for future product launches and enhance market competitiveness.
- Strategic Outlook: Apogee Therapeutics is viewed as reaching a critical inflection point in immunology by 2026, and successful new therapy launches could improve financial health and attract more investor interest.
- Industry Engagement: The company presented at the 2025 Citi Annual Global Healthcare Conference, and while detailed outcomes were not provided, such events help raise brand awareness and may facilitate future collaboration opportunities.
See More
Great Point Partners Increases Stake in Apogee Therapeutics
- Share Acquisition: On February 17, 2026, Great Point Partners purchased 70,000 shares of Apogee Therapeutics (APGE) for an estimated $4.41 million, indicating strong confidence in the company's future prospects.
- Asset Value Increase: This transaction boosted the fund's quarter-end position value by $16.15 million, reflecting the dual impact of new share acquisitions and stock price appreciation, demonstrating the effectiveness of its biotechnology investment strategy.
- Increased Ownership Stake: Apogee Therapeutics now represents 9.15% of the fund's reportable assets, making it the largest holding, which underscores the fund's trust in its biologic platform, particularly in the concentrated investment in immunology.
- Strong Financial Position: As of February 17, 2026, APGE shares were priced at $69.64, up 100% over the past year, showcasing robust market performance and potential growth opportunities, which are likely to continue attracting investor interest.
See More
Great Point Partners Increases Apogee Holdings by 70,000 Shares
- Share Increase: Great Point Partners increased its position in Apogee Therapeutics by 70,000 shares in Q4 2026, with an estimated transaction value of $4.41 million, reflecting confidence in the company's future prospects.
- Market Value Growth: The fund's quarter-end position value rose by $16.15 million, demonstrating the dual impact of new share acquisitions and stock price appreciation, further solidifying its investment stance in the biotech sector.
- Investment Concentration: Apogee has become the fund's largest holding, now accounting for approximately 9.15% of reportable assets, indicating its significance in the portfolio and a strong focus on the biopharmaceutical field.
- Strong Financial Position: With $913 million in cash, Apogee's financial health appears robust, providing a runway into the second half of 2028, which mitigates financial risk and supports future R&D and market expansion.
See More
Apogee Therapeutics Announces Upcoming Conference Participation
- Management Conference Schedule: Apogee Therapeutics will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, showcasing its latest advancements in biotechnology, which is expected to attract investor interest.
- Multiple Conference Participation: The management team will also attend the UBS Biotech Summit on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026, further enhancing the company's visibility and investor relations in the biotech sector.
- Product Development Outlook: Apogee is advancing its antibody programs, particularly Zumilokibart (APG777) for Atopic Dermatitis (AD) and asthma, aiming to fill gaps in existing therapies and meet market demand.
- Market Positioning and Goals: The company is committed to achieving best-in-class efficacy through monotherapies and combinations targeting four validated indications, striving to lead in the immunology and inflammation market and enhance patient treatment experiences.
See More
Perceptive Advisors Increases Stake in Apogee Therapeutics
- Share Increase: On February 17, 2026, Perceptive Advisors disclosed a purchase of 978,662 shares of Apogee Therapeutics, with an estimated transaction value of $61.64 million, indicating strong confidence in the company.
- Stake Proportion Rise: Following this acquisition, Perceptive Advisors' total holdings in Apogee reached 2,330,651 shares, representing 3.14% of its 13F AUM, reflecting ongoing interest in the biotech sector.
- Outstanding Stock Performance: As of February 17, 2026, Apogee's shares were priced at $69.64, up 99.4% over the past year, significantly outperforming the S&P 500 by 78.67 percentage points, showcasing market optimism for its future growth.
- Positive Financial Outlook: Apogee anticipates fiscal 2026 sales of approximately $1.39 billion, with adjusted EPS between $3.40 and $3.50, indicating potential in clinical development and commercialization, attracting long-term investor interest.
See More
